Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sangamo Therapeutics's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.08.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.34.
During the past 3 years, the average EBIT per Share Growth Rate was 33.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 20.70% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 4.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Sangamo Therapeutics's EBIT per Share or its related term are showing as below:
LTS:0R1D'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -118.6 Med: -4.4 Max: 33.4
Current: 33.4
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Sangamo Therapeutics was 33.40% per year. The lowest was -118.60% per year. And the median was -4.40% per year.
LTS:0R1D's 3-Year EBIT Growth Rate is ranked better than 72.59% of 1171
companies
in the Biotechnology industry
Industry Median: 15.4
vs LTS:0R1D: 33.40
Sangamo Therapeutics (LTS:0R1D) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Sangamo Therapeutics EBIT per Share Related Terms
Sangamo Therapeutics EBIT per Share Historical Data
* Premium members only.
The historical data trend for Sangamo Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.34
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sangamo Therapeutics (LTS:0R1D) has a EBIT per Share of $-0.34 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sangamo Therapeutics and its competitors. According to the industry distribution chart, Sangamo Therapeutics ranks #321 out of 1171 companies in the Biotechnology industry, placing it in the top 27.4%.
Is Sangamo Therapeutics' EBIT per Share too high?
Sangamo Therapeutics' current EBIT per Share is $-0.34. Based on the distribution chart, Sangamo Therapeutics ranks #321 out of 1171 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sangamo Therapeutics has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sangamo Therapeutics' EBIT per Share compare to SER and ABVC?
According to the Biotechnology industry distribution chart, Sangamo Therapeutics ranks #321 out of 1171 companies for EBIT per Share. This puts Sangamo Therapeutics in the upper half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,171 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sangamo Therapeutics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sangamo Therapeutics's current EBIT per Share is $-0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sangamo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sangamo Therapeutics (LTS:0R1D) is currently considered Possible Value Trap. The stock's GF Value™ is $0.19, compared to a current price of $0.11 — trading 42.2% below its estimated fair value. The current EBIT per Share is $-0.34. Sangamo Therapeutics' overall GF Score™ is 35/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Sangamo Therapeutics (LTS:0R1D), the current EBIT per Share is $-0.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sangamo Therapeutics (LTS:0R1D) Overvalued in 2026?
Based on GuruFocus' analysis, Sangamo Therapeutics stock appears to be undervalued.
The current stock price of $0.11 is trading 42.2% below its estimated GF Value™ of $0.19.
GuruFocus considers Sangamo Therapeutics to be Possible Value Trap.
Key valuation signals for LTS:0R1D:
EBIT per Share: $-0.34
GF Value™: $0.19 vs. price of $0.11 (42.2% below fair value)
No single metric tells the full story. See the LTS:0R1D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its neurology development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases and development of novel engineered adeno-associated virus, or AAV, capsids to deliver its therapies to the intended neurological targets. The group's pipeline products are Small Fiber Neuropathy, Prion Disease, Tauopathies, ALS/FTD, Huntington's Disease, Fabry Disease, and Hemophilia A.
35GF Score
Get the complete analysis for LTS:0R1D
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R1D has been successfully added to your 
